TY - JOUR T1 - Survival Clustering web-based application – A deeper look at risk profiles for METABRIC JF - medRxiv DO - 10.1101/2023.05.18.23290062 SP - 2023.05.18.23290062 AU - Yuan Gu AU - Mingyue Wang AU - Yishu Gong AU - Song Jiang AU - Zhen Li Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/05/25/2023.05.18.23290062.abstract N2 - Medical doctors frequently rely on assistance tools during the decision-making process or when determining suitable chemotherapy options. These tools can take the form of recommendation systems, online test calculators, or web-based applications. They provide support not only in making recommendations but also in conducting thorough profile investigations of patients. Previous researchers have developed web-based survival analysis tools in the cancer survival field. However, many of these tools provide only basic functionality and rely on simplistic models, offering only a superficial understanding of the data. In this study, we undertake a comprehensive analysis of risk profiles using survival clustering techniques applied to a real-world dataset and developed an accessible online Shiny application to facilitate easier utilization of our findings. By leveraging survival clustering, we aim to uncover distinct subgroups based on survival patterns and identify unique risk profiles associated with breast cancer patients. Our online app provides a user-friendly interface for researchers and clinicians to explore the results, enabling them to gain valuable insights into the complex landscape of breast cancer risk profiles. This interactive tool offers a more accessible means of understanding and utilizing the implications of our research in personalized medicine and clinical decision-making.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used (or will use) ONLY openly available human data that were originally located at: https://www.cbioportal.org/study/clinicalData?id=brca_metabricI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.cbioportal.org/study/clinicalData?id=brca_metabric ER -